UNLIMITED TURBO LONG - ELI LILLY & CO | Real-time Euronext Paris 10:27:51 2024-07-12 am EDT | ||
| 22.34 EUR | +8.71% |
|
| Current month | +5.17% | ||
| 1 month | +35.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 22.34 | +8.71% |
| 24-07-11 | 20.56 | -8.01% |
| 24-07-10 | 22.34 | +9.13% |
| 24-07-09 | 20.48 | +3.02% |
| 24-07-08 | 19.88 | +1.74% |
Real-time Euronext Paris
Last update July 12, 2024 at 10:27 am EDT
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| OP8NB | |
| ISIN | FRBNPP06JSY1 |
| Date issued | 2024-03-04 |
| Strike | 705.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.02 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.64 € |
|---|---|
| Lowest since issue | 3.03 € |
| Spread | 0.05 € |
| Spread % | 0.23% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Certificates
- OP8NB Certificat
